Mednet Logo
SpecialtiesMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

What are magic mouthwash alternatives that you would recommend?

24
9 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Toledo Clinic

Many of our patients will make their own DIY MMW per Phil's My Pharmacist (YouTube) instructions -- uses benzocaine/Cepacol lozenges -- they say it's much more effective than the compounded one from the pharmacy. It is also more economical.If the majority of bothersome mucositis is in the oral cavit...

Do you routinely offer PARP inhibitor maintenance therapy to germline BRCA1/2+, FIGO stage II serous ovarian carcinoma patients after adjuvant chemotherapy?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Utah School of Medicine

We are not offering PARPi maintenance in early stage disease at this time. We are in line with the data showing benefit in advanced stage disease. While the data are compelling, you must remember that that these medications 1) have side effects including risk of MDS and 2) can be used in the recurre...

What is your treatment approach for a MSS metastatic colorectal cancer patient who has progressed on FOLFOX and FOLFIRI?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Massachusetts General Hospital

If the patient is RAS/BRAF wildtype, then I would pursue anti-EGFR antibody-based therapy. If the patient has KRAS mutant colorectal cancer and continues to have a good performance status, then I would pursue clinical trials if possible. Many of the clinical trials in this space are phase I or phase...

How do you treat a female with a diagnosis of invasive apocrine carcinoma of the breast?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Warren Alpert Medical School of Brown University

While some data suggests that apocrine cancers may not respond as well to chemotherapy as ‘usual’ triple negative breast cancers, 80-90% are basal-like by gene expression analysis. I treat them the same way - with adjuvant chemotherapy for Stage I cancers (or Stage II-III patients who didn’t receive...

How do you approach patients with osteosarcoma of the maxilla for neoadjuvant chemotherapy?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

The SOC treatment for “jaw” OS is a margin negative surgical resection. If indeed feasible (not always the case), this applies to maxillary tumors. Jaw OS does respond poorly to standard chemotherapy. In our experience, HD Ifosfamide may be a better choice than standard Dox/CDDP. We use this approac...

How would you approach the treatment of checkpoint-inhibitor-mediated temporal arteritis?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · Johns Hopkins School of Medicine

Temporal arteritis or GCA is a rare immune related adverse event due to immune checkpoint inhibitor (ICI) therapy. Corticosteroids are the first line treatment, along with holding the ICI. As there have been limited cases, there is not evidence for IVIG in this setting.

For a very high risk prostate cancer with relatively no elevation in PSA but no distant or nodal metastasis would you consider “neoadjuvant” ADT and chemotherapy prior to EBRT?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

This is a very challenging scenario in dealing with men who have M0 N0 but very high risk disease with a Gleason 10 (grade group 5) locally advanced tumor. Recent data supports a very poor outcome for these low PSA high grade patients when treated with IMRT and ADT alone (Mahal BA et al Eur Urol 201...

What endocrine therapy would you recommend to a premenopausal female with early stage HR+ Breast cancer who is transitioning from female to male and currently on testosterone?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic College of Medicine and Science

There is not a lot of data, and so shared decision-making is paramount, with the following considerations: Acknowledging the limited data in this setting, how would this patient feel about stopping testosterone? While many patients feel that T is critical for identity, others may not feel that way. ...

What is the best radiation dose to treat primary cutaneous B cell lymphoma?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Yale School of Medicine

For a small (1-2cm lesion) of these subtypes, 30Gy is usually adequate. For larger/thicker lesions, consider 36Gy. Electrons with bolus or orthovoltage/superficial therapy.

What is the role of "adjuvant" systemic chemotherapy in patients previously resected NSCLC, now with isolated solitary relapsed brain lesion, treated with resection and SBRT?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Wexner Medical Center at The Ohio State University

Most of the data/publications for treating isolated, solitary lesions (brain or otherwise) revolve around the local therapy (stereotactic radiosurgery or conventional surgery for example), and there is not much data regarding the use of systemic therapy in this setting. There is a recent article sug...